Skip to content
Products & Services · Total revenues

TEZSPIRE — Total revenues

Amgen TEZSPIRE — Total revenues decreased by 96.0% to $343M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 95.8%, from $8.15B to $343M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates growing market penetration, successful commercial execution, or expanded clinical indications for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in physician prescribing patterns.

Detailed definition

This metric represents the total gross sales generated by the specific therapeutic product line within the company's por...

Peer comparison

Comparable to product-specific revenue reporting in other biopharmaceutical companies, often benchmarked against consensus estimates for key growth drivers and blockbusters.

Metric ID: amgn_segment_tezspire_total_revenues

Historical Data

37 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25Q3 '25Q3 '25Q4 '25Q4 '25Q1 '26Q1 '26
Value$6.53B$6.71B$6.85B$6.24B$42.5M$6.59B$42.5M$6.65B$42.5M$6.84B$42.5M$6.11B$96M$6.99B$133M$6.9B$161M$8.2B$177M$7.45B$173M$8.39B$234M$8.5B$269M$9.09B$296M$8.15B$285M$9.18B$342M$9.56B$377M$9.87B$474M$8.62B$343M
QoQ Change+2.8%+2.1%-8.9%-99.3%>999%-99.4%>999%-99.4%>999%-99.4%>999%-98.4%>999%-98.1%>999%-97.7%>999%-97.8%>999%-97.7%>999%-97.2%>999%-96.8%>999%-96.7%>999%-96.5%>999%-96.3%>999%-96.1%>999%-95.2%>999%-96.0%
YoY Change+1.0%-99.3%-0.8%-99.4%-0.1%-99.4%-2.1%-98.5%+5.9%-98.0%+3.8%-97.6%+19.8%-97.4%+22.0%-97.2%+20.1%-96.7%+23.2%-96.1%+10.9%-96.4%+9.4%-96.2%+9.4%-95.9%+12.4%-95.6%+8.6%-94.8%+5.8%-95.8%
Range$42.5M$9.87B
CAGR-27.9%
Avg YoY Growth-43.9%
Median YoY Growth-48.5%

Frequently Asked Questions

What is Amgen's tezspire — total revenues?
Amgen (AMGN) reported tezspire — total revenues of $343M in Q1 2026.
How has Amgen's tezspire — total revenues changed year-over-year?
Amgen's tezspire — total revenues decreased by 95.8% year-over-year, from $8.15B to $343M.
What does tezspire — total revenues mean?
The total revenue generated from sales of the specific therapeutic product.